Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A
Article first published online: 6 MAY 2008
Copyright © 2008 ISUOG. Published by John Wiley & Sons, Ltd.
Ultrasound in Obstetrics & Gynecology
Volume 31, Issue 6, pages 618–624, June 2008
How to Cite
Kagan, K. O., Wright, D., Baker, A., Sahota, D. and Nicolaides, K. H. (2008), Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol, 31: 618–624. doi: 10.1002/uog.5331
- Issue published online: 27 MAY 2008
- Article first published online: 6 MAY 2008
- Manuscript Accepted: 3 MAR 2008
- 3Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 2005; 25: 221–226., , , , .
- 6First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008; 31: 493–502., , , , .
- 7Applied Regression Analysis (3rd edn). Wiley: New York, NY, 1998., .
- 10Office for National Statistics. Birth Statistics. Review of the Registrar General on births and patterns of family building in England and Wales. Series FM1, number 29–31. Stationery Office: London, 2000–2002.
- 11National Screening Committee. National Screening Committee Policy—Down's Syndrome Screening (compiled July 2006). http://www.library.nhs.uk/screening/ViewResource.aspx?resID = 35689 [Accessed 23 December 2007].